Hematology & Oncology Doctors in Bethpage, NY Accepting Medicare

3 Hematology & Oncology doctors found. Showing 1 - 3

Mir Javed Iqbal, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4277 Hempstead Tpk, Suite 107, Bethpage, NY 11714 Phone: 516-735-9210    Fax: 516-735-9247

Romeo D Balagot, MD Internal Medicine - Hematology & Oncology Medicare: May Accept Medicare Assignments Practice Location: 4277 Hempstead Turnpike, Suite 107, Bethpage, NY 11714 Phone: 516-731-0124    Fax: 516-731-6160

Aruna Gupta, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1055 Stewart Ave, Bethpage, NY 11714 Phone: 516-938-0100    Fax: 516-938-0120

News Archive

Micro Imaging announces the settlement with Divine Capital regarding issuance of convertible debentures

Micro Imaging Technology, Inc. has announced that it and Divine Capital Markets, LLC have settled all claims and counterclaims asserted in a lawsuit pending in New York State Supreme Court arising from the issuance of convertible debentures.

20 million more Oxford-AstraZeneca vaccines donated to COVAX

A further ten million Oxford-AstraZeneca vaccines have been sent by the UK to COVAX, with 10 million more due to be delivered in the coming weeks to some of the world's most vulnerable people.

Drug prices may fall by up to 82 percent in Australia

There is good news for patients who regularly take drugs for conditions such as high blood pressure and diabetes. The prices of these medicines in Australia could be reduced sharply from next year.

Adolescents with PTSD, conduct disorders more likely to misidentify facial expressions

Adolescents with posttraumatic stress disorder (PTSD) symptoms are more likely to misidentify sad and angry faces as fearful, while teens with symptoms of conduct disorder tend to interpret sad faces as angry, finds a study by NYU's Steinhardt School of Culture, Education, and Human Development.

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

Read more Medical News

› Verified 1 days ago